Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Qiagen beats Street EPS

Qiagen (FSE:QIA; QGENF) reported second quarter EPS of $0.08, beating the Street consensus by a penny and

Read the full 173 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE